Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $23.80
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $23.80
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) have been assigned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $23.80.
据MarketBeat报道,追踪Iovance BioTreateutics,Inc.(纳斯达克代码:IOVA-GET Rating)的12位分析师给出了该公司股票的平均建议为“适度买入”。一名投资分析师对该股的评级为卖出,两名分析师给出了持有评级,七名分析师给出了该公司的买入评级。在去年发布了该股报告的经纪商中,1年的平均价格目标是23.80美元。
Several brokerages have commented on IOVA. Wells Fargo & Company restated an "equal weight" rating and issued a $14.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, August 18th. Truist Financial lowered their price objective on shares of Iovance Biotherapeutics to $18.00 in a report on Tuesday, August 23rd. JMP Securities restated a "buy" rating and issued a $25.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, September 12th. Robert W. Baird decreased their target price on shares of Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a research note on Friday, August 5th. Finally, Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $31.00 to $30.00 in a research note on Friday, August 5th.
几家券商对艾奥瓦发表了评论。富国银行(Wells Fargo&Company)在8月18日(星期四)的一份报告中重申了“同等权重”的评级,并为Iovance BioTreateutics的股票发布了14.00美元的目标价。在8月23日星期二的一份报告中,Truist Financial将Iovance BioTreateutics的股票目标价下调至18.00美元。JMP证券在9月12日(星期一)的一份报告中重申了“买入”评级,并对Iovance BioTreateutics的股票发布了25.00美元的目标价。8月5日,罗伯特·W·贝尔德在一份研究报告中将Iovance BioTreateutics的股票目标价从34.00美元下调至25.00美元,并为该公司设定了“跑赢大盘”的评级。最后,Chardan Capital在8月5日星期五的一份研究报告中将Iovance BioTreateutics的股票目标价从31.00美元下调至30.00美元。
Institutional Investors Weigh In On Iovance Biotherapeutics
机构投资者参与Iovance BioTreatetics
Institutional investors and hedge funds have recently made changes to their positions in the company. Herold Advisors Inc. bought a new stake in shares of Iovance Biotherapeutics during the first quarter valued at approximately $33,000. Spire Wealth Management purchased a new stake in Iovance Biotherapeutics in the first quarter worth approximately $47,000. Lazard Asset Management LLC boosted its holdings in Iovance Biotherapeutics by 38.5% in the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 934 shares during the last quarter. Retirement Group LLC boosted its holdings in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Iovance Biotherapeutics by 1,459.9% in the second quarter. Nisa Investment Advisors LLC now owns 6,614 shares of the biotechnology company's stock worth $73,000 after purchasing an additional 6,190 shares during the last quarter.
机构投资者和对冲基金最近对他们在该公司的头寸进行了调整。Herold Advisors Inc.在第一季度购买了Iovance BioTreateutics的新股份,价值约33,000美元。Spire Wealth Management在第一季度购买了Iovance BioTreateutics的新股份,价值约4.7万美元。Lazard Asset Management LLC在第一季度将其在Iovance BioTreateutics的持股增加了38.5%。Lazard Asset Management LLC在上个季度额外购买了934股后,现在拥有3357股这家生物技术公司的股票,价值5.5万美元。退休集团LLC在第一季度增持了Iovance BioTreateutics 85.1%的股份。在上个季度又购买了2,000股后,退休集团现在持有这家生物技术公司4,350股股票,价值72,000美元。最后,NISA Investment Advisors LLC在第二季度将其在Iovance BioTreateutics的持股增加了1,459.9%。NISA Investment Advisors LLC现在持有这家生物技术公司6614股股票,价值7.3万美元,在上个季度又购买了6190股。
Iovance Biotherapeutics Trading Up 0.5 %
Iovance生物治疗公司股价上涨0.5%
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the firm posted ($0.53) EPS. Research analysts forecast that Iovance Biotherapeutics will post -2.53 earnings per share for the current fiscal year.
IOVance BioTreateutics(纳斯达克代码:IOVA-GET Rating)最近一次发布季度收益数据是在8月4日(星期四)。这家生物技术公司公布了该季度每股收益(0.63美元),低于普遍预期的(0.60美元)和(0.03美元)。去年同期,该公司公布的每股收益为0.53美元。研究分析师预测,Iovance BioTreateutics本财年每股收益将达到2.53美元。
Iovance Biotherapeutics Company Profile
艾万斯生物治疗公司简介
(Get Rating)
(获取评级)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Iovance BioTreateutics,Inc.是一家临床阶段的生物技术公司,专注于开发癌症免疫治疗产品并将其商业化,以利用患者免疫系统的力量根除癌细胞。该公司正在进行6项第二阶段临床研究,包括其主要候选产品lifileucel的C-144-01,用于治疗转移性黑色素瘤;C-145-04,其候选产品lifileucel,用于复发、转移或持续性宫颈癌;以及C-145-03,其候选产品LN-145,用于治疗复发和/或转移性头颈部鳞状细胞癌。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- 免费获取StockNews.com关于Iovance生物疗法(IOVA)的研究报告
- 麦格纳国际是您的汽车和电动汽车一站式库存
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat:回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 让Paychex股票为您努力工作
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《爱的生物疗法日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Iovance BioTreateutics和相关公司的最新新闻和分析师评级的每日简要摘要。